Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Partnering with providers
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice
The structures of numerous small molecule and peptide-type orthosteric or allosteric ligands have been resolved
The GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide sit behind the STEP (NEJM, 2021), SURMOUNT (NEJM, 2022), and SURMOUNT-OSA (NEJM, 2024) evidence, and the clinical picture does not change with the price tag
Phase 3 interim results of two new molecules were presented with simultaneous publications during Kidney Week
Elevates NAD+ and S-adenosylmethionine (SAM) levels, shifting metabolic flux toward energy expenditure and away from fat storage 1-4
US$ 28.36
US$ 22.58
US$ 23.62
US$ 21.02
